Switching to Tasigna After Gleevec Therapy Can Achieve Deeper Molecular Response
Perjeta, Herceptin & Docetaxel Combination Extended Survival in HER2-Positive Disease
Two Regorafenib Trials Demonstrate Efficacy, Improve Overall and Progression-Free Survival
Volasertib Shows Response In 31 Percent of Acute Myeloid Leukemia Patients
Breast Cancer Risk Increases With Repeated CT Imaging
Scatter Radiation from Mammography Presents No Increased Cancer Risk
MRI, 3D Ultrasound Combination Can Guide Prostate Biopsies
Perifosine, Sorafenib Combination Well Tolerated in Several Lymphomas
NCI-Approved CTEP Trials For the Month of December
FDA Approves 35 Medicines In Fiscal 2012, Eight in Cancer
Trending Stories
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Did peer review fail? Nature Medicine’s chronotherapy paper retraction raises questions
- Mail-out colorectal cancer screening programs extend, rather than replace, clinical care
- A chronotherapy study in Nature Medicine showed dramatic results. Then it was retracted.
The phase III trial claimed a staggering boost to OS and PFS when immunochemotherapy was given before 3 p.m. - OMB’s plan to increase political control of science faces stiff opposition on Capitol Hill
- Cancer patients with Medicare Advantage have access to fewer providers than Medicare patients, cross-sectional study finds
